{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:04:47Z","timestamp":1790643887481,"version":"4.1.0"},"reference-count":69,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2009,10,30]],"date-time":"2009-10-30T00:00:00Z","timestamp":1256860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,10,30]]},"abstract":"<jats:title>Summary<\/jats:title>\n               <jats:p>Intravenous immunoglobulin (IVIg) is used increasingly in the management of patients with neurological conditions. The efficacy and safety of IVIg treatment in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and Guillain\u2013Barr\u00e9 syndrome (GBS) have been established clearly in randomized controlled trials and summarized in Cochrane systematic reviews. However, questions remain regarding the dose, timing and duration of IVIg treatment in both disorders. Reports about successful IVIg treatment in other neurological conditions exist, but its use remains investigational. IVIg has been shown to be efficacious as second-line therapy in patients with dermatomyositis and suggested to be of benefit in some patients with polymyositis. In patients with inclusion body myositis, IVIg was not shown to be effective. IVIg is also a treatment option in exacerbations of myasthenia gravis. Studies with IVIg in patients with Alzheimer's disease have reported increased plasma anti-A\u03b2 antibody titres associated with decreased A\u03b2 peptide levels in the cerebrospinal fluid following IVIg treatment. These changes at the molecular level were accompanied by improved cognitive function, and large-scale randomized trials are under way.<\/jats:p>","DOI":"10.1111\/j.1365-2249.2009.04025.x","type":"journal-article","created":{"date-parts":[[2009,10,30]],"date-time":"2009-10-30T18:33:24Z","timestamp":1256927604000},"page":"34-42","source":"Crossref","is-referenced-by-count":59,"title":["Clinical applications of intravenous immunoglobulins in neurology"],"prefix":"10.1093","volume":"158","author":[{"given":"R A C","family":"Hughes","sequence":"first","affiliation":[{"name":"National Hospital for Neurology and Neurosurgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M C","family":"Dalakas","sequence":"additional","affiliation":[{"name":"Imperial College, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D R","family":"Cornblath","sequence":"additional","affiliation":[{"name":"Johns Hopkins University, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Latov","sequence":"additional","affiliation":[{"name":"Weill Cornell Medical College, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M E","family":"Weksler","sequence":"additional","affiliation":[{"name":"Weill Cornell Medical College, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Relkin","sequence":"additional","affiliation":[{"name":"Weill Cornell Medical College, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,10,30]]},"reference":[{"key":"2021122708525360300_b1","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0140-6736(81)92400-4","article-title":"High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood","volume":"1","author":"Imbach","year":"1981","journal-title":"Lancet"},{"key":"2021122708525360300_b2","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0022-510X(85)90173-X","article-title":"Plasma and gammaglobulin infusion in chronic inflammatory polyneuropathy","volume":"70","author":"Vermeulen","year":"1985","journal-title":"J Neurol Sci"},{"key":"2021122708525360300_b3","first-page":"CD001797","article-title":"Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy [update of Cochrane Database Syst Rev 2002;(2):CD001797","volume":"1","author":"Eftimov","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"2021122708525360300_b4","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1474-4422(07)70329-0","article-title":"Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial","volume":"7","author":"Hughes","year":"2008","journal-title":"Lancet Neurol"},{"key":"2021122708525360300_b5","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1212\/WNL.38.10.1639","article-title":"Treatment of Guillain\u2013Barr\u00e9 Syndrome with high dose gammaglobulin","volume":"38","author":"Kleyweg","year":"1988","journal-title":"Neurology"},{"key":"2021122708525360300_b6","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1056\/NEJM199204233261705","article-title":"A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain\u2013Barr\u00e9 syndrome. Dutch Guillain\u2013Barr\u00e9 Study Group","volume":"326","author":"Van Der Mech\u00e9","year":"1992","journal-title":"N Engl J Med"},{"key":"2021122708525360300_b7","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0140-6736(96)09095-2","article-title":"Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain\u2013Barr\u00e9 syndrome","volume":"349","author":"Plasma Exchange\/Sandoglobulin Guillain\u2013Barr\u00e9 Syndrome Trial Group","year":"1997","journal-title":"Lancet"},{"key":"2021122708525360300_b8","first-page":"CD002063","article-title":"Intravenous immunoglobulin for Guillain\u2013Barr\u00e9 syndrome","volume":"1","author":"Hughes","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"2021122708525360300_b9","first-page":"CD004429","article-title":"Intravenous immunoglobulin for multifocal motor neuropathy","volume":"2","author":"Van Schaik","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"2021122708525360300_b10","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1001\/archneur.1995.00540350039015","article-title":"Successful treatment of neuropathies in patients with diabetes mellitus","volume":"52","author":"Krendel","year":"1995","journal-title":"Arch Neurol"},{"key":"2021122708525360300_b11","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1196\/annals.1361.121","article-title":"Response of vasculitic peripheral neuropathy to intravenous immunoglobulin","volume":"1051","author":"Levy","year":"2005","journal-title":"Ann NY Acad Sci"},{"key":"2021122708525360300_b12","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1136\/jnnp.2005.084533","article-title":"Intravenous immunoglobulin treatment in painful sensory neuropathy without sensory ataxia associated with Sjogren's syndrome","volume":"77","author":"Kizawa","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2021122708525360300_b13","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1468-1331.2008.02246.x","article-title":"EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases","volume":"15","author":"Elovaara","year":"2008","journal-title":"Eur J Neurol"},{"key":"2021122708525360300_b14","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/j.tmrv.2007.01.002","article-title":"Guidelines on the use of intravenous immune globulin for neurologic conditions","volume":"21","author":"Feasby","year":"2007","journal-title":"Transfus Med Rev"},{"key":"2021122708525360300_b15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jns.2007.02.017","article-title":"Effective treatment of experimental autoimmune neuritis with human immunoglobulin","volume":"256","author":"Lin","year":"2007","journal-title":"J Neurol Sci"},{"key":"2021122708525360300_b16","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"N Engl J Med"},{"key":"2021122708525360300_b17","first-page":"CD002277","article-title":"Intravenous immunoglobulin for myasthenia gravis","volume":"2","author":"Gajdos","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"2021122708525360300_b18","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1212\/01.wnl.0000318281.98220.6f","article-title":"Intravenous immunoglobulin in relapsing\u2013remitting multiple sclerosis: a dose-finding trial","volume":"71","author":"Fazekas","year":"2008","journal-title":"Neurology"},{"key":"2021122708525360300_b19","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1046\/j.1468-1331.2002.00501.x","article-title":"Intravenous immunoglobulin G for the treatment of relapsing\u2013remitting multiple-sclerosis: a meta-analysis","volume":"9","author":"Sorensen","year":"2002","journal-title":"Eur J Neurol"},{"key":"2021122708525360300_b20","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1212\/WNL.44.6.1184","article-title":"Reversal of subacute paraneoplastic cerebellar syndrome with intravenous immunoglobulin","volume":"44","author":"Counsell","year":"1994","journal-title":"Neurology"},{"key":"2021122708525360300_b21","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1136\/jnnp.60.4.388","article-title":"Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodies","volume":"60","author":"Uchuya","year":"1996","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2021122708525360300_b22","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1212\/WNL.54.6.1370","article-title":"Treatment of acute disseminated encephalomyelitis with intravenous immunoglobulin","volume":"54","author":"Sahlas","year":"2000","journal-title":"Neurology"},{"key":"2021122708525360300_b23","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1212\/WNL.44.6.1030","article-title":"Medical treatment of Rasmussen's syndrome (chronic encephalitis and epilepsy): effect of high-dose steroids or immunoglobulins in 19 patients","volume":"44","author":"Hart","year":"1994","journal-title":"Neurology"},{"key":"2021122708525360300_b24","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/ana.20339","article-title":"Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset","volume":"56","author":"Dauvilliers","year":"2004","journal-title":"Ann Neurol"},{"key":"2021122708525360300_b25","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1136\/jnnp.2003.033399","article-title":"Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease","volume":"75","author":"Dodel","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2021122708525360300_b26","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S0531-5565(02)00029-3","article-title":"Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals","volume":"37","author":"Weksler","year":"2002","journal-title":"Exp Gerontol"},{"key":"2021122708525360300_b27","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1212\/WNL.57.5.801","article-title":"Reduced levels of amyloid beta-peptide antibody in Alzheimer disease","volume":"57","author":"Du","year":"2001","journal-title":"Neurology"},{"key":"2021122708525360300_b28","article-title":"18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease","author":"Relkin","year":"2008","journal-title":"Neurobiol Aging"},{"key":"2021122708525360300_b29","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jneuroim.2004.10.021","article-title":"Gene expression profiling in chronic inflammatory demyelinating polyneuropathy","volume":"159","author":"Renaud","year":"2005","journal-title":"J Neuroimmunol"},{"key":"2021122708525360300_b30","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1212\/01.wnl.0000188879.19900.b7","article-title":"Macrophage clustering as a diagnostic marker in sural nerve biopsies of patients with CIDP","volume":"65","author":"Sommer","year":"2005","journal-title":"Neurology"},{"key":"2021122708525360300_b31","first-page":"127","article-title":"The clinical usefulness of high dose intravenous immunoglobulin therapy for chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy","volume":"51","author":"Kubori","year":"1999","journal-title":"No To Shinkeil"},{"key":"2021122708525360300_b32","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1212\/WNL.56.4.445","article-title":"Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuroapthy","volume":"56","author":"Mendell","year":"2001","journal-title":"Neurology"},{"issue":"12","key":"2021122708525360300_b33","first-page":"S8","article-title":"Timing of clinical response to immune globulin intravenous, 10% caprylate\/chromatography purified (IGIV-C) in chronic inflammatory demyelinating polyneuropathy (CIDP)","volume":"64","author":"Latov","year":"2008","journal-title":"Ann Neurol"},{"key":"2021122708525360300_b34","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/brain\/119.4.1067","article-title":"Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double blind, placebo-controlled, cross over study","volume":"119","author":"Hahn","year":"1996","journal-title":"Brain"},{"key":"2021122708525360300_b35","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1002\/mus.21000","article-title":"Length dependent weakness and electrophysiologic signs of secondary axonal loss in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"38","author":"Harbo","year":"2008","journal-title":"Muscle Nerve"},{"key":"2021122708525360300_b36","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1529-8027.2006.00105.x","article-title":"Dose of intravenous immunoglobulins in chronic inflammatory demyelinating polyneuropathy","volume":"11","author":"Rajabally","year":"2006","journal-title":"J Peripher Nerv Syst"},{"key":"2021122708525360300_b37","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1016\/j.clinph.2007.05.001","article-title":"Long-term effects of intravenous immunoglobulin in CIDP","volume":"118","author":"Vucic","year":"2007","journal-title":"Clin Neurophys"},{"key":"2021122708525360300_b38","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S0140-6736(05)67665-9","article-title":"Guillain\u2013Barr\u00e9 syndrome","volume":"366","author":"Hughes","year":"2005","journal-title":"Lancet"},{"key":"2021122708525360300_b39","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1474-4422(08)70215-1","article-title":"Clinical features, pathogenesis, and treatment of Guillain\u2013Barr\u00e9 syndrome","volume":"7","author":"Van Doorn","year":"2008","journal-title":"Lancet Neurol"},{"key":"2021122708525360300_b40","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1093\/brain\/119.6.2053","article-title":"The Italian Guillain\u2013Barr\u00e9 Study Group. The prognosis and main prognostic indicators of Guillain-Barr\u00e9 syndrome. A multicentre prospective study of 297 patients","volume":"119","year":"1996","journal-title":"Brain"},{"key":"2021122708525360300_b41","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ana.410440512","article-title":"Electrophysiological classification of Guillain\u2013Barr\u00e9 syndrome: clinical associations and outcome. Plasma Exchange\/Sandoglobulin Guillain\u2013Barr\u00e9 Syndrome Trial Group","volume":"44","author":"Hadden","year":"1998","journal-title":"Ann Neurol"},{"key":"2021122708525360300_b42","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/0140-6736(91)90606-P","article-title":"Clinical and electrophysiological aspects of acute paralytic disease of children and young adults in northern China","volume":"338","author":"McKhann","year":"1991","journal-title":"Lancet"},{"key":"2021122708525360300_b43","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/mus.880150415","article-title":"Guillain\u2013Barr\u00e9 syndrome in children: clinical course, electrodiagnosis, and prognosis","volume":"15","author":"Bradshaw","year":"1992","journal-title":"Muscle Nerve"},{"key":"2021122708525360300_b44","first-page":"CD002063","article-title":"Intravenous immunoglobulin for Guillain\u2013Barr\u00e9 syndrome","volume":"1","author":"Hughes","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"2021122708525360300_b45","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3109\/00365549509019016","article-title":"Intravenous immunoglobulin treatment in children with Guillain\u2013Barr\u00e9 syndrome","volume":"27","author":"G\u00fcrses","year":"1995","journal-title":"Scand J Infect Dis"},{"key":"2021122708525360300_b46","first-page":"223","article-title":"Intravenous immunoglobulin in children with Guillain\u2013Barr\u00e9 syndrome","volume":"16","author":"Wang","year":"2001","journal-title":"J Appl Clin Pediatr"},{"key":"2021122708525360300_b47","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1542\/peds.2004-1324","article-title":"Intravenously administered immunoglobulin in the treatment of childhood Guillain\u2013Barr\u00e9 syndrome: a randomized trial","volume":"116","author":"Korinthenberg","year":"2005","journal-title":"Pediatrics"},{"key":"2021122708525360300_b48","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11926-007-0047-5","article-title":"Advances in the immunobiology and treatment of inflammatory myopathies","volume":"9","author":"Dalakas","year":"2007","journal-title":"Curr Rheumatol Rep"},{"key":"2021122708525360300_b49","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1001\/jama.291.19.2367","article-title":"Intravenous immunoglobulin in autoimmune neuromuscular diseases","volume":"29","author":"Dalakas","year":"2004","journal-title":"JAMA"},{"key":"2021122708525360300_b50","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/ncprheum0140","article-title":"Mechanisms of disease: signaling pathways and immunobiology of inflammatory myopathies","volume":"2","author":"Dalakas","year":"2006","journal-title":"Nat Clin Pract Rheumatol"},{"key":"2021122708525360300_b51","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/cei.1996.104.s1.55","article-title":"Clinical benefits and immunopathological correlates of intravenous immune globulin in the treatment of inflammatory myopathies","volume":"104","author":"Dalakas","year":"1996","journal-title":"Clin Exp Immunol"},{"key":"2021122708525360300_b52","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1006\/clim.1999.4823","article-title":"Downregulation of TGF-beta1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin","volume":"94","author":"Amemiya","year":"2000","journal-title":"Clin Immunol"},{"key":"2021122708525360300_b53","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/art.10053","article-title":"Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients","volume":"46","author":"Cherin","year":"2002","journal-title":"Arthritis Rheum"},{"key":"2021122708525360300_b54","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11910-009-0013-x","article-title":"Inclusion body myositis: review of recent literature","volume":"9","author":"Greenberg","year":"2009","journal-title":"Curr Neurol Neurosci Rep"},{"key":"2021122708525360300_b55","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1212\/WNL.48.3.712","article-title":"Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study","volume":"48","author":"Dalakas","year":"1997","journal-title":"Neurology"},{"key":"2021122708525360300_b56","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1212\/WNL.56.3.323","article-title":"A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM","volume":"56","author":"Dalakas","year":"2001","journal-title":"Neurology"},{"key":"2021122708525360300_b57","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1093\/brain\/awh518","article-title":"Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes","volume":"128","author":"Raju","year":"2005","journal-title":"Brain"},{"key":"2021122708525360300_b58","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/373523a0","article-title":"Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein","volume":"373","author":"Games","year":"1995","journal-title":"Nature"},{"key":"2021122708525360300_b59","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/22124","article-title":"Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse","volume":"400","author":"Schenk","year":"1999","journal-title":"Nature"},{"key":"2021122708525360300_b60","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/35050110","article-title":"A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease","volume":"408","author":"Janus","year":"2000","journal-title":"Nature"},{"key":"2021122708525360300_b61","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/35050116","article-title":"A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease","volume":"408","author":"Morgan","year":"2000","journal-title":"Nature"},{"key":"2021122708525360300_b62","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1212\/01.WNL.0000073623.84147.A8","article-title":"Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization","volume":"61","author":"Orgogozo","year":"2003","journal-title":"Neurology"},{"key":"2021122708525360300_b63","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","article-title":"Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial","volume":"64","author":"Gilman","year":"2005","journal-title":"Neurology"},{"key":"2021122708525360300_b64","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/78682","article-title":"Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease","volume":"6","author":"Bard","year":"2000","journal-title":"Nat Med"},{"key":"2021122708525360300_b65","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.bbrc.2007.07.107","article-title":"Reduced serum level of antibodies against amyloid beta peptide is associated with aging in Tg2576 mice","volume":"361","author":"Sohn","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"2021122708525360300_b66","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/ana.21475","article-title":"Autoantibodies against \u03b2-amyloid are common in Alzheimer's disease and help control plaque burden","volume":"65","author":"Kellner","year":"2009","journal-title":"Ann Neurol"},{"key":"2021122708525360300_b67","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/ana.10253","article-title":"Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease","volume":"52","author":"Dodel","year":"2002","journal-title":"Ann Neurol"},{"key":"2021122708525360300_b68","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1136\/jnnp.2003.033399","article-title":"Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease","volume":"75","author":"Dodel","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2021122708525360300_b69","first-page":"P4","volume-title":"Effects of uninterrupted intravenous immunoglobulin treatment of Alzheimer's disease for 9 months","author":"Tsakanikas","year":"2008"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2249.2009.04025.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/158\/Supplement_1\/34\/41925868\/j.1365-2249.2009.04025.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/158\/Supplement_1\/34\/41925868\/j.1365-2249.2009.04025.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T16:21:59Z","timestamp":1641054119000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/158\/Supplement_1\/34\/6428797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,30]]},"references-count":69,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2009,10,30]]},"published-print":{"date-parts":[[2009,10,30]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2249.2009.04025.x","relation":{},"ISSN":["1365-2249","0009-9104"],"issn-type":[{"value":"1365-2249","type":"electronic"},{"value":"0009-9104","type":"print"}],"subject":[],"published-other":{"date-parts":[[2009,12]]},"published":{"date-parts":[[2009,10,30]]}}}